Addition of isatuximab to carfilzomib–dexamethasone has been hailed “a new standard of care” for patients with relapsed multiple myeloma. The anti-CD38 monoclonal antibody is already approved in combination with pomalidomide and dexamethasone in many countries for relapsed and refractory multiple myeloma. The phase 3 IKEMA trial comparing isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone found the addition ...
Isatuximab another string in the bow for management of RRMM
By Mardi Chapman
15 Jun 2021